title: Cografting with polymer-encapsulated human nerve growth factor-secreting cells and chromaffin cell survival and behavioral recovery in hemiparkinsonian rats.
abstract: Encapsulated cell grafting is one approach for the delivery of neurotransmitters and/or neurotrophic factors to the brain. Baby hamster kidney (BHK) cells were genetically modified to secrete high levels of human nerve growth factor (hNGF). Following polymer encapsulation, these cells were implanted into the left lateral ventricle or the left striatum 1.5 mm away from striatally cografted unencapsulated adrenal medullary chromaffin cells in hemiparkinsonian rats. Although the animals receiving adrenal medulla alone or adrenal medulla with intraventricular hNGF-secreting cell grafting did not show recovery of apomorphine-induced rotational behavior, the animals receiving adrenal medulla with intrastriatal hNGF-secreting cell implants showed a significant recovery of rotational behavior 2 and 4 weeks after transplantation. Histological analysis revealed that in animals receiving adrenal medulla with intraventricular hNGF-secreting cell grafting, the number of tyrosine hydroxylase-immunoreactive (TH-IR) surviving chromaffin cells tended to be higher (approximately five to six times) than in animals receiving adrenal medulla alone; however, this increase did not reach statistical significance. In contrast, in animals receiving adrenal medullary cells together with intrastriatal hNGF-secreting cells, the number of TH-IR surviving chromaffin cells was more than 20 times higher than that in animals receiving adrenal medullary cells alone. Analysis of retrieved capsules revealed that hNGF continued to be released by encapsulated BHK-hNGF cells after 4 weeks in vivo. Moreover, histological analysis confirmed the presence of numerous viable encapsulated BHK-hNGF cells. These results indicate the potential use of intrastriatal implantation of encapsulated hNGF-secreting cells for augmenting the survival of cografted chromaffin cells as well as promoting the functional recovery of hemiparkinsonian rats. These data indicate that this approach may have potential application for treating Parkinson's disease.
authors.affiliation: Department of Neurological Surgery, Okayama University Medical School, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Date
authors.forename: T
authors.initials: T
authors.lastname: Ohmoto
authors.forename: T
authors.initials: T
authors.lastname: Imaoka
authors.forename: T
authors.initials: T
authors.lastname: Ono
authors.forename: J P
authors.initials: JP
authors.lastname: Hammang
authors.forename: J
authors.initials: J
authors.lastname: Francis
authors.forename: C
authors.initials: C
authors.lastname: Greco
authors.forename: D F
authors.initials: DF
authors.lastname: Emerich
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D016380:Brain Tissue Transplantation; D002470:Cell Survival / Q000502:physiology*; D002838:Chromaffin System / Q000502:physiology*; D006224:Cricetinae; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D009414:Nerve Growth Factors / Q000502:physiology*; D009474:Neurons / Q000637:transplantation*; D010300:Parkinson Disease / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D009414:Nerve Growth Factors